Scleroderma
Half of rheumatic rare disease patients face three-year wait for diagnosis
People living with rare autoimmune rheumatic diseases endure major obstacles to diagnosis, treatment and lifestyle according to a new study published by the Rare Autoimmune Rheumatic Diseases Alliance (RAIRDA). Continue reading
Devastating impact of arthritis across all aspects of society is highlighted in new campaign
The current and future impact of osteoarthritis and rheumatoid arthritis on the economy, the NHS, families and individuals is revealed in a campaign from Arthritis Research UK. Continue reading
UK’s largest arthritis charities merge
Arthritis Care will merge into Arthritis Research UK and work as one charity from October 2017. Continue reading
Longer-lasting pain relief thanks to compound – new developments
Experts are developing compounds that could allow the pain-relieving effects of ibuprofen to last longer, they report in Molecular Pharmaceutics. And the approach could also be used to deliver other drugs orally that currently can only be taken intravenously.
Metal-organic frameworks are compounds made of metal ions linked to organic ligands, for drug delivery. Active ingredients can be packed inside the metal organic frameworks. They are porous, and some dissolve in water so are good candidates for drug couriers.
The researchers loaded ibuprofen into metal organic frameworks. The compounds were found to reach the bloodstream (of mice) quickly and lasted for twice as long as ibuprofen salts, which are the active ingredient in liquid gel formulations.
For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.
The pain can be horrendous and I battle with depression, but I have to get through it for my children, explains Fiona Brien
I was diagnosed with systemic sclerosis, Raynaud’s phenomenon, rheumatoid arthritis and underlining lupus in 1982 when I was just nine years old. Continue reading